PD153035 hydrochloride [153436-54-5]
Katalog-Nummer A8199-10mg
Size : 10mg
Marke : APExBIO Technology
Contact local distributor :
Telefonnummer : +1 850 650 7790
- Home
- Signaling Pathways
- JAK/STAT Signaling
- EGFR
- PD153035 hydrochloride
PD153035 hydrochloride
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
PD153035 (4-(3-Bromoanilino)-6,7-dimethoxyquinazoline) is an extremely potent epidermal growth factor receptor (EGFR) inhibitor that competitively binds at the ATP site with the half maximal inhibition concentration IC50 of 0.025 nM resulting in the inhibition of the tyrosine kinase activity of the EGFR [1].
PD153035 has been found to inhibit EGF-dependent EGFR phosphorylation in a variety of human cancer cell lines over-expressing EGFRs, which include A431, Difi, DU145, MDA-MB-468, ME180 and C4i, with IC50 of 0.22 μM, 0.3 μM, 0.4 μM, 0.68 μM, 0.95 μM and 2.5 μM respectively leading to suppression of proliferation and clonogenicity in those cell lines [2].
Besides exerting potent inhibition against EGFRs, PD153035 also inhibits the closely related HER2/neu receptor but to a lesser degree [2].
References:
[1] Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HD, Fry DW, Kraker AJ, Denny WA. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76.
[2] Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3(11):2099-106.
- 1. Duggan BM, Foley KP, et al."Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia." Sci Rep. 2017 May 8;7(1):1578. PMID:28484277
| Physical Appearance | A solid |
| Storage | Store at RT |
| M.Wt | 396.67 |
| Cas No. | 153436-54-5 |
| Formula | C16H14BrN3O2·HCl |
| Synonyms | ZM252868,PD153035 HCL |
| Solubility | insoluble in EtOH; insoluble in H2O; ≥3.97 mg/mL in DMSO with gentle warming |
| Chemical Name | N-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine |
| SDF | Download SDF |
| Canonical SMILES | COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Br)OC |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
| Cell lines | A panel of cancer cell lines overexpressing various levels of EGF receptor and HER2/neu. |
| Preparation method | The solubility of this compound in DMSO is limited. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
| Reacting condition | 0.5-2800 nM; 2 h |
| Applications | In EGF receptor-overexpressing cell lines, PD153035 caused a dose-dependent decrease in ligand-inducedEGF receptor phosphorylation. PD153035 only inhibited HER2/neu phosphorylation at the highest concentrations tested (1400-2800 nM). PD153035 also inhibited cell proliferation in EGF receptor-positive cell lines. |
| Animal experiment [2]: | |
| Animal models | Immunodeficient nude mice xenografted with A431 human epidermoid tumors |
| Dosage form | i.p. dose of 80 mg/kg |
| Application | In immunodeficient nude mice xenografted with A431 human epidermoid tumors, PD153035 rapidly suppressed the tyrosine phosphorylation of the EGF receptor by 80-90% in the tumors. Following a single i.p. dose of 80 mg/kg, the drug levels in the plasma and tumor rose to 50 and 22 μM within 15 minutes. |
| Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| References: [1] Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3(11):2099-106. [2]. Kunkel MW1, Hook KE, Howard CT, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 1996;13(4):295-302. | |
| Description | PD153035 is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM. | |||||
| Targets | EGFR | EGFR | ||||
| IC50 | 5.2 pM (Ki) | 29 pM | ||||